Characterisation of the GRAF gene promoter and its methylation in patients with acute myeloid leukaemia and myelodysplastic syndrome

British Journal of Cancer

Volumn 94, Issue 2, 2006, Pages 323-332

  Bojesen, S E ^a   Ammerpohl, O ^b   Weinhausl A ^c   Haas, O A ^d   Mettal, H ^e   Bohle, R M ^f   Borkhardt, A ^g   Fuchs, U ^g  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^d CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

AML; GRAF; MDS; Promoter methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING SITE; BONE MARROW; CLINICAL ARTICLE; CPG ISLAND; DNA FLANKING REGION; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GUANOSINE TRIPHOSPHATASE REGULATOR ASSOCIATED WITH THE FOCAL ADHESION KINASE GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; BASE SEQUENCE; CHILD; GTPASE-ACTIVATING PROTEINS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; METHYLATION; MOLECULAR SEQUENCE DATA; MYELODYSPLASTIC SYNDROMES; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 31444455401     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602939     Document Type: Article

References (44)

1. Ammerpohl O, Schmitz A, Steinmüller L, Renkawitz R (1998) Repression of the mouse M-lysozyme gene involves both hindrance of enhancer factor binding to the methylated enhancer and histone deacetylation. Nucleic Acids Res 26: 5256-5260
2. Ammerpohl O, Short ML, Asbrand C, Schmitz A, Renkawitz R (1997) Complex protein binding to the mouse M-lysozyme gene downstream enhancer involves single-stranded DNA binding. Gene 200: 75-84
3. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174
4. Bednarik DP, Duckett C, Kim SU, Perez VL, Griffis K, Guenthner PC, Folks TM (1991) DNA CpG methylation inhibits binding of NF-kappa B proteins to the HIV- 1 long terminal repeat cognate DNA motifs. New Biol 3: 969-976
5. Ben Hattar J, Beard P, Jiricny J (1989) Cytosine methylation in CTF and Sp1 recognition sites of an HSV tk promoter: effects on transcription in vivo and on factor binding in vitro. Nucleic Acids Res 17: 10179-10190
6. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE (2002) Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1: 937-941
7. Borkhardt A, Bojesen S, Haas OA, Fuchs U, Bartelheimer D, Loncarevic IF, Bohle RM, Harbott J, Repp R, Jaeger U, Viehmann S, Henn T, Korth P, Scharr D, Lampert F (2000) The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA 97: 9168-9173
8. Comb M, Goodman HM (1990) CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 18: 3975-3982
9. Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257: 2041-2048
10. Dignam JD, Lebovitz RM, Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489
11. Dobrovic A, Simpfendorfer D (1997) Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57: 3347-3350
12. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463
13. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y (2005) Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 3: 325-334
14. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196: 261-282
15. Gaston K, Fried M (1995) CpG methylation and the binding of YY1 and ETS proteins to the Surf-1/Surf-2 bidirectional promoter. Gene 157: 257-259
16. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535
17. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM (1997) Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 272: 22322-22329
18. Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9: 359-367
19. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054
20. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826
21. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704
22. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875
23. Hildebrand JD, Taylor JM, Parsons JT (1996) An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase. Mol Cell Biol 16: 3169-3178
24. Iguchi-Ariga SM, Schaffner W (1989) CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 3: 612-619
25. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, Isaacs WB (1997) Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19: 90-96
26. Juttermann R, Li E, Jaenisch R (1994) Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797-11801
27. Karagiannis TC, Smith AJ, El OA (2004) Radio- and chemo-sensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor trichostatin A. Hell J Nucl Med 7: 184-191
28. Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36: 110-119
29. Kovesdi I, Reichel R, Nevins JR (1987) Role of an adenovirus E2 promoter binding factor in E1A-mediated coordinate gene control. Proc Natl Acad Sci USA 84: 2180-2184
30. Liu ZJ, Zhang XB, Zhang Y, Yang X (2004) Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells. FEBS Lett 567: 327-332
31. Marks PA, Miller T, Richon VM (2003) Histone deacetylases. Curr Opin Pharmacol 3: 344-351
32. Marks PA, Richon VM, Breslow R, Rifkind RA (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483
33. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216
34. Melki JR, Vincent PC, Clark SJ (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59: 3730-3740
35. Nickel J, Short ML, Schmitz A, Eggert M, Renkawitz R (1995) Methylation of the mouse M-lysozyme downstream enhancer inhibits heterotetrameric GABP binding. Nucleic Acids Res 23: 4785-4792
36. Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, Ozasa K, Watanabe Y, Hayashi K, Maeda K, Kinoshita S, Matsumura T, Ohnishi Y et al (1997) Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet 98: 43-49
37. Panagopoulos I, Kitagawa A, Isaksson M, Morse H, Mitelman F, Johansson B (2004) MLL/GRAF fusion in an infant acute monocytic leukemia (AML M5b) with a cytogenetically cryptic ins(5;11)(q31;q23q23). Genes Chromosomes Cancer 41: 400-404
38. QIU RG, CHEN J, MCCORMICK F, SYMONS M (1995) A role for Rho in Ras transformation. Proc Natl Acad Sci USA 92: 11781-11785
39. Shapiro DJ, Sharp PA, Wahli WW, Keller MJ (1988) A high-efficiency HeLa cell nuclear transcription extract. DNA 7: 47-55
40. Weiner MP, Costa GL, Schoettlin W, Cline J, Mathur E, Bauer JC (1994) Site-directed mutagenesis of double-stranded DNA by the polymerase chain reaction. Gene 151: 119-123
41. Wilda M, Perez AV, Bruch J, Woessmann W, Metzler M, Fuchs U, Borkhardt A (2005) Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5). Genes Chromosomes Cancer 43: 424-426
42. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, Sakai T (2004) Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 23: 5340-5349
43. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416-7419
44. Zhu WG, Otterson GA (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Cancer Agents 3: 187-199